KRONOX vs TATVA: Stock Comparison

Kronox Lab Sciences Limited vs Tatva Chintan Pharma Chem Ltd

Live data: 31 July 2026, 4:08 PM IST • Source: NSE and company filings

Tatva Chintan Pharma Chem Ltd is the larger company by market capitalisation. Kronox Lab Sciences Limited shows a lower P/E, a higher ROE and a higher dividend yield, while Tatva Chintan Pharma Chem Ltd shows faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Kronox Lab Sciences Limited and Tatva Chintan Pharma Chem Ltd on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, KRONOX is more favourable on 8 of 13 scored metrics and TATVA on 5These counts are context-free and are not an overall rating.

Key Differences

Market Cap
TATVA is the larger company
₹4,174 Cr vs ₹563 Cr
P/E Ratio
KRONOX has a lower P/E
20.32x vs 76.19x
P/B Ratio
KRONOX has a lower P/B
4.84x vs 5.01x
EPS
TATVA has higher earnings per share
₹22 vs ₹7.45
Dividend Yield
KRONOX has a higher dividend yield
0.33% vs 0.06%
Revenue Growth (TTM YoY)
TATVA has faster revenue growth
24.4% vs 0%
EPS Growth (TTM YoY)
TATVA has faster EPS growth
907.5% vs 26.7%
Qtr Sales Growth
TATVA has stronger quarterly sales growth
43% vs 0%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricKRONOXTATVA
SectorChemicalsChemicals
IndustrySpecialty ChemicalsSpecialty Chemicals

Price

MetricKRONOXTATVA
Live Price₹151.3₹1,788.2
Day Change-0.52%6.43%
Volume36,7121.79 L
52-Week High₹184.31₹1,835
52-Week Low₹96₹976.4
Distance from 52W High-17.91%-2.55%

Valuation

MetricKRONOXTATVA
Market Cap₹563 Cr₹4,174 Cr
P/E Ratio20.32x76.19x
P/B Ratio4.84x5.01x
EPS₹7.45₹22
Book Value₹31.64₹334
Dividend Yield0.33%0.06%

Growth

MetricKRONOXTATVA
Revenue Growth (TTM YoY)0%24.4%
EPS Growth (TTM YoY)26.7%907.5%
Qtr Sales Growth0%43%
Qtr Profit Growth26.6%155%

Profitability & Leverage

MetricKRONOXTATVA
ROE26.8%5.53%
ROCE36%7.14%
Net Margin27.21%8.31%
Operating Margin33.9%19.4%
Debt to Equity0.01x0.15x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricKRONOXTATVA
Promoter Holding74.21%72.02%
FII Holding0.04% 0.04 pp3.93% 0.11 pp
DII Holding2.07% 0.02 pp3.11% 0.12 pp
Public Holding23.67% 0.01 pp20.94% 0.23 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Kronox Lab Sciences Limited and Tatva Chintan Pharma Chem Ltd.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.